HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Learn More
Open in Screener

PROK

ProKidney Corp

Last Close
Sep 17  •  03:12PM ET
2.55
Dollar change
-0.07
Percentage change
-2.86 %
Healthcare • Biotechnology • USA • NASD
Peers: FMS DVA OPK NEPH RMTI AKBA MNKD ARDX ADMA PDEX
 | Held by: VXF SCHA VTI SCHB MSSM
Index- P/E- EPS (ttm)-0.56 Insider Own26.41% Shs Outstand133.42M Perf Week17.83%
Market Cap748.98M Forward P/E- EPS next Y-0.55 Insider Trans2.88% Shs Float99.34M Perf Month0.20%
Enterprise Value1.80B PEG- EPS next Q-0.14 Inst Own30.46% Short Float8.44% Perf Quarter196.67%
Income-72.47M P/S1413.17 EPS this Y16.81% Inst Trans-21.20% Short Ratio0.61 Perf Half Y162.49%
Sales0.53M P/B- EPS next Y-6.48% ROA-16.64% Short Interest8.38M Perf YTD50.60%
Book/sh-7.51 P/C2.54 EPS next 5Y7.27% ROE- 52W High7.13 -64.30% Perf Year6.49%
Cash/sh1.00 P/FCF- EPS past 3/5Y11.32% - ROIC- 52W Low0.46 452.92% Perf 3Y-73.82%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin-927.51% Volatility17.04% 9.13% Perf 5Y-
Dividend TTM- EV/Sales3397.39 EPS Y/Y TTM4.97% Oper. Margin-33456.74% ATR (14)0.28 Perf 10Y-
Dividend Ex-Date- Quick Ratio11.48 Sales Y/Y TTM- Profit Margin-13752.18% RSI (14)52.10 Recom2.12
Dividend Gr. 3/5Y- - Current Ratio11.48 EPS Q/Q23.18% SMA206.26% Beta1.79 Target Price5.83
Payout- Debt/Eq- Sales Q/Q- SMA50-9.48% Rel Volume0.11 Prev Close2.62
Employees204 LT Debt/Eq- EarningsAug 12 AMC SMA20058.80% Avg Volume13.84M Price2.55
IPOJun 30, 2021 Option/ShortYes / Yes EPS/Sales Surpr.10.03% - Trades Volume1,329,909 Change-2.86%
Date Action Analyst Rating Change Price Target Change
Jun-30-25Downgrade BofA Securities Neutral → Underperform $1
Sep-30-24Initiated JP Morgan Neutral
Sep-10-24Initiated Guggenheim Buy $6
Mar-07-24Resumed Morgan Stanley Equal-Weight $3
Jan-02-24Downgrade BofA Securities Buy → Neutral
Jul-25-23Initiated BTIG Research Buy $16
Dec-21-22Initiated Jefferies Buy $15
Nov-10-22Initiated Morgan Stanley Equal-Weight $13
Oct-18-22Initiated UBS Buy $18
Oct-14-22Initiated Citigroup Buy $16
Show Previous Ratings
Aug-27-25 07:30AM
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
(GlobeNewswire)
Aug-12-25 04:01PM
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
(GlobeNewswire) +5.80%
Jul-22-25 11:03AM
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement
(Insider Monkey) -5.28%
04:52AM
Meet the Biotech Stock That Rocketed 775% Higher
(Motley Fool)
Jul-20-25 12:35AM
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)
(Insider Monkey)
12:00PM Loading…
Jul-17-25 12:00PM
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
(Zacks) -5.63%
10:00AM
Best Momentum Stocks to Buy for July 17th
(Zacks)
06:40AM
This Biotech Stock Jumped Over 600% in Just Days After Releasing Promising Clinical Trial Data. And Its Market Cap Is Still Only $2 Billion. But Is It a Buy?
(Motley Fool)
05:38AM
New Strong Buy Stocks for July 17th
(Zacks)
Jul-16-25 12:00PM
ProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?
(Zacks) +10.68%
Jul-15-25 07:30AM
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
(GlobeNewswire) -8.67%
Jul-14-25 09:45AM
ProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?
(Barchart) -18.72%
Jul-12-25 07:30AM
'Story' stocks are smoking hot in 2025. This is how it could end badly for investors.
(MarketWatch)
Jul-09-25 12:26PM
PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study
(Zacks) +16.35%
07:51AM
ProKidney, Meta & EssilorLuxottica, Apple COO: Trending Tickers
(Yahoo Finance Video)
07:30AM Loading…
07:30AM
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
(GlobeNewswire)
Jul-08-25 05:09PM
ProKidney's stock rockets on 'intriguing' news, but analyst doesn't recommend buying
(MarketWatch) +515.00%
07:00AM
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
(GlobeNewswire)
Jul-01-25 12:43PM
ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware
(GlobeNewswire)
Jun-30-25 09:36AM
Circle initiated, Disney upgraded: Wall Street's top analyst calls
(The Fly) -11.46%
May-12-25 04:15PM
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
(GlobeNewswire) +15.79%
Mar-21-25 09:55AM
Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK)
(Zacks)
Mar-17-25 07:30AM
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
(GlobeNewswire) +5.73%
Jan-07-25 07:30AM
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Nov-26-24 07:30AM
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
(GlobeNewswire)
Nov-12-24 07:30AM
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
(GlobeNewswire)
Nov-05-24 07:30AM
ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference
(GlobeNewswire)
Oct-22-24 07:02PM
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp
(GuruFocus.com) -8.11%
Oct-14-24 07:30AM
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024
(GlobeNewswire)
Oct-09-24 07:30AM
ProKidney to Participate in the UBS Virtual Organ Restoration Day
(GlobeNewswire)
01:33PM Loading…
Sep-04-24 01:33PM
ProKidney drops Phase III CKD study to focus on US market and save up to $175m
(Clinical Trials Arena) -9.17%
Sep-03-24 07:30AM
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.
(GlobeNewswire)
Aug-27-24 07:30AM
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
(GlobeNewswire) -7.53%
Aug-09-24 07:00AM
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
(GlobeNewswire)
Jun-27-24 05:52AM
PROK Stock Earnings: ProKidney Reported Results for Q4 2023
(InvestorPlace) +6.61%
Jun-26-24 02:10PM
Hedge Fund and Insider Trading News: Crispin Odey, Boaz Weinstein, Ken Griffin, Greenlight Capital, Eisler Capital, ProKidney Corp (PROK), Essex Property Trust Inc (ESS), and More
(Insider Monkey)
Jun-17-24 07:00AM
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters' Option
(GlobeNewswire) +6.96%
Jun-11-24 09:35PM
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
(GlobeNewswire) -19.87% +23.55%
07:40AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
(InvestorPlace)
Jun-10-24 04:15PM
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
(GlobeNewswire) -5.33%
07:32AM
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
(InvestorPlace)
06:30AM
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
(GlobeNewswire)
May-29-24 07:00AM
ProKidney to Participate in the Jefferies Global Healthcare Conference
(GlobeNewswire) +6.74%
May-21-24 07:00AM
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
(GlobeNewswire)
May-10-24 03:43PM
ProKidney Corp Reports First Quarter 2024 Financial Results
(GuruFocus.com) +7.66%
01:54PM
PROK Stock Earnings: ProKidney Beats EPS for Q1 2024
(InvestorPlace)
07:48AM
ProKidney Q1 Loss Unchanged From Year Earlier
(MT Newswires)
07:00AM
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
(GlobeNewswire)
Mar-25-24 06:05AM
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
(GlobeNewswire)
Mar-21-24 07:49PM
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights
(GlobeNewswire) -6.16%
Feb-29-24 04:05PM
ProKidney to Participate in Jefferies Biotech on the Bay Summit
(GlobeNewswire)
Dec-29-23 08:22AM
Chamath Palihapitiya Stocks: 12 Stocks Pumped in the Last 10 Years
(Insider Monkey)
Dec-13-23 09:55AM
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock Now
(Zacks) +9.60%
Nov-30-23 06:05AM
ProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business Officer
(GlobeNewswire) -10.16%
Nov-24-23 06:40AM
7 Penny Stocks With Low Floats and High Short Interest
(InvestorPlace)
Nov-21-23 06:05AM
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx Conference
(GlobeNewswire) +5.68%
Nov-17-23 01:38PM
ProKidney Corp. (NASDAQ:PROK) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-16-23 09:35AM
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)
(Zacks) -11.51%
Nov-14-23 07:04AM
ProKidney Corp (PROK) Reports Q3 Financial Results: Focus on Chronic Kidney Disease Trials
(GuruFocus.com) -5.00%
06:05AM
ProKidney Reports Third Quarter Financial Results
(GlobeNewswire)
Nov-13-23 05:02PM
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT ) for Diabetic CKD and Provides Corporate Updates
(GlobeNewswire)
Oct-30-23 04:12PM
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023
(GlobeNewswire) +12.29%
Oct-17-23 09:35AM
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks) -7.93%
Oct-16-23 02:50PM
Is Chamath Palihapitiya Giving Up on ProKidney (PROK) Stock?
(InvestorPlace)
Oct-12-23 03:05PM
Why Shares of ProKidney Were Dropping Thursday
(Motley Fool) -31.45%
Sep-06-23 12:14PM
ProKidney confirms it will expand HQ complex, add 50 jobs in Winston-Salem
(American City Business Journals)
Sep-05-23 06:05AM
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare Conference
(GlobeNewswire)
Aug-31-23 10:33AM
3 Biotech Stocks Due for a Massive Short Squeeze
(InvestorPlace)
Aug-29-23 01:16PM
ProKidney confirmed as company seeking incentives to expand in Forsyth County
(American City Business Journals)
Aug-11-23 02:21PM
ProKidney reports $38.8 million loss in Q2 FY2023 as it advances clinical trials and prepares for Greensboro manufacturing expansion
(American City Business Journals)
Aug-10-23 04:10PM
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Jul-18-23 06:05AM
ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC
(GlobeNewswire)
Jul-17-23 06:05AM
ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization
(GlobeNewswire) +6.65%
Jun-13-23 12:05PM
ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC
(GlobeNewswire)
Jun-01-23 04:05PM
ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
(GlobeNewswire) -7.66%
May-11-23 04:01PM
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
(GlobeNewswire)
May-04-23 06:05AM
ProKidney to Present at the BofA Securities Health Care Conference 2023
(GlobeNewswire)
Apr-25-23 02:00PM
We're Interested To See How ProKidney (NASDAQ:PROK) Uses Its Cash Hoard To Grow
(Simply Wall St.) -8.73%
Mar-28-23 04:12PM
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
(GlobeNewswire) -7.39%
Mar-03-23 06:05AM
ProKidney to Participate in TD Cowens 43rd Annual Health Care Conference
(GlobeNewswire)
Jan-11-23 07:48AM
ProKidneys stock jumps 29%
(MarketWatch)
Jan-10-23 04:05PM
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
(GlobeNewswire) +9.57%
Dec-27-22 11:05AM
Chamath Palihapitiya Stocks: 10 Stocks Picked in the Last 10 Years
(Insider Monkey) -5.82%
08:46AM
A Look At The Intrinsic Value Of ProKidney Corp. (NASDAQ:PROK)
(Simply Wall St.)
Dec-22-22 06:05AM
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
(GlobeNewswire)
Nov-16-22 11:22AM
ProKidney (NASDAQ:PROK) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.)
Nov-14-22 06:05AM
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
(GlobeNewswire)
Nov-11-22 04:05PM
ProKidney to Participate in Upcoming Investor Conferences
(GlobeNewswire) +6.85%
Nov-03-22 06:05AM
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
(GlobeNewswire)
Oct-14-22 12:00PM
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrologys Kidney Week 2022
(GlobeNewswire)
Sep-23-22 06:15AM
ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
(GlobeNewswire)
Sep-08-22 06:05AM
ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
(GlobeNewswire)
Aug-31-22 06:05AM
ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations
(GlobeNewswire) +12.28%
Aug-11-22 05:30PM
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
(GlobeNewswire) +7.55%
10:01AM
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
(GlobeNewswire)
Jul-20-22 08:00AM
ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
(GlobeNewswire)
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weber Darin J.Chief Regulatory OfficerJul 08 '25Sale3.02103,480312,5100Jul 09 04:28 PM
DARIN J WEBEROfficerJul 08 '25Proposed Sale0.61103,48062,761Jul 08 04:20 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 22 '25Buy0.71387,393276,36673,842,723Apr 24 04:15 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 17 '25Buy0.7525,00018,69073,455,330Apr 21 04:37 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 16 '25Buy0.75100,00074,82073,430,330Apr 18 04:15 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 15 '25Buy0.70468,000326,00973,330,330Apr 16 05:04 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 14 '25Buy0.73268,105194,59172,862,330Apr 16 05:04 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 10 '25Buy0.611,032,218627,69272,592,325Apr 14 04:30 PM
Control Empresarial de CapitalAdd'l Rep. Persons-see Ex.99-1Apr 11 '25Buy0.611,9001,15572,594,225Apr 14 04:30 PM
Weber Darin J.Chief Regulatory OfficerSep 19 '24Sale2.5016,41241,030103,480Sep 20 04:44 PM
DARIN J WEBEROfficerSep 19 '24Proposed Sale2.3916,41239,225Sep 19 04:27 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

RPRX

Royalty Pharma plc

Last Close
Sep 17  •  03:12PM ET
35.77
Dollar change
+0.35
Percentage change
0.99 %
Healthcare • Biotechnology • USA • NASD
RPRX Royalty Pharma plc daily Stock Chart
Peers: BIIB REGN VRTX GILD INCY ALNY EXEL NBIX MDGL DKNG
 | Held by: VTI VO VXF VFLO VTV VOE VYM IWR VHT SCHM
Index- P/E15.57 EPS (ttm)2.30 Insider Own21.19% Shs Outstand432.29M Perf Week-1.13%
Market Cap20.86B Forward P/E7.12 EPS next Y5.02 Insider Trans-0.03% Shs Float340.69M Perf Month-0.42%
Enterprise Value31.39B PEG1.47 EPS next Q1.04 Inst Own80.47% Short Float4.88% Perf Quarter3.50%
Income1.02B P/S9.05 EPS this Y8.45% Inst Trans4.29% Short Ratio4.66 Perf Half Y7.06%
Sales2.31B P/B2.44 EPS next Y12.17% ROA5.67% Short Interest16.62M Perf YTD40.22%
Book/sh14.68 P/C32.34 EPS next 5Y10.62% ROE15.92% 52W High38.00 -5.87% Perf Year29.04%
Cash/sh1.11 P/FCF8.28 EPS past 3/5Y8.57% -21.51% ROIC7.63% 52W Low24.05 48.73% Perf 3Y-18.03%
Dividend Est.0.92 (2.58%) EV/EBITDA17.06 Sales past 3/5Y-0.38% 4.52% Gross Margin- Volatility2.48% 2.28% Perf 5Y-9.31%
Dividend TTM0.87 (2.43%) EV/Sales13.62 EPS Y/Y TTM53.03% Oper. Margin79.81% ATR (14)0.83 Perf 10Y-
Dividend Ex-DateAug 15, 2025 Quick Ratio1.26 Sales Y/Y TTM3.04% Profit Margin44.26% RSI (14)46.69 Recom1.50
Dividend Gr. 3/5Y7.30% - Current Ratio1.26 EPS Q/Q-68.63% SMA20-1.03% Beta0.59 Target Price44.67
Payout43.94% Debt/Eq1.26 Sales Q/Q7.71% SMA50-1.58% Rel Volume0.59 Prev Close35.42
Employees99 LT Debt/Eq1.11 EarningsAug 06 BMO SMA2009.39% Avg Volume3.57M Price35.77
IPOJun 16, 2020 Option/ShortYes / Yes EPS/Sales Surpr.10.53% 4.95% Trades Volume1,862,693 Change0.99%
Date Action Analyst Rating Change Price Target Change
May-16-25Initiated Morgan Stanley Overweight $51
Jun-03-24Downgrade UBS Buy → Neutral $28
Jun-14-22Resumed UBS Buy $47
May-13-22Initiated Scotiabank Sector Outperform $53
Apr-27-22Initiated Goldman Buy $56
Apr-14-22Upgrade JP Morgan Neutral → Overweight $50
Apr-06-22Resumed Morgan Stanley Overweight $48
Oct-29-21Upgrade Citigroup Neutral → Buy $50
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Show Previous Ratings
Today 02:27PM
TD Cowen Maintains a Buy on Royalty Pharma (RPRX)
(Insider Monkey)
12:43AM
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
(StockStory)
Sep-16-25 09:28AM
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
(Insider Monkey)
Sep-11-25 11:13AM
Royalty Pharma plc (RPRX) Commits $300M to Zenas' Obexelimab Program
(Insider Monkey)
07:00AM
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation
(GlobeNewswire)
07:30AM Loading…
Sep-10-25 07:30AM
Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market
(GlobeNewswire)
Sep-04-25 04:15PM
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
(GlobeNewswire)
Sep-02-25 08:30PM
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
(GlobeNewswire)
07:15AM
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
(GlobeNewswire)
Aug-29-25 02:57PM
Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase
(Insider Monkey)
05:05AM
Royalty Pharma plc (RPRX) Boosts Growth with $885M Amgen Imdelltra Royalty Deal
(Insider Monkey)
04:54AM
Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines
(Insider Monkey)
Aug-25-25 01:19PM
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
(Benzinga)
08:29AM
Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales
(BioPharma Dive)
06:33AM
Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug
(Reuters)
06:10AM Loading…
06:10AM
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million
(GlobeNewswire)
06:00AM
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
(Business Wire)
Aug-13-25 04:15PM
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
(GlobeNewswire)
01:35AM
5 Insightful Analyst Questions From Royalty Pharma's Q2 Earnings Call
(StockStory)
Aug-12-25 09:10AM
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT
(Insider Monkey)
03:18AM
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments
(StockStory)
Aug-10-25 11:31PM
Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
(StockStory)
Aug-06-25 05:45PM
Analyst Report: Royalty Pharma plc
(Morningstar Research)
04:02PM
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
(GlobeNewswire)
09:30AM
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 Earnings
(Zacks)
08:20AM
Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates
(Zacks)
08:08AM
Royalty Pharma (NASDAQ:RPRX) Misses Q2 Revenue Estimates
(StockStory)
07:22AM
Royalty Pharma: Q2 Earnings Snapshot
(Associated Press Finance)
07:00AM
Royalty Pharma Reports Second Quarter 2025 Results
(GlobeNewswire)
Aug-05-25 09:15AM
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
(Zacks)
11:21PM Loading…
Aug-04-25 11:21PM
Earnings To Watch: Royalty Pharma (RPRX) Reports Q2 Results Tomorrow
(StockStory)
Jul-30-25 10:00AM
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
(Zacks)
12:02AM
2 Reasons to Watch RPRX and 1 to Stay Cautious
(StockStory)
Jul-18-25 08:15AM
Royalty Pharma Declares Third Quarter 2025 Dividend
(GlobeNewswire)
Jul-17-25 08:15AM
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
(GlobeNewswire)
Jul-16-25 04:15PM
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
(GlobeNewswire)
Jul-01-25 06:20AM
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
(Zacks)
Jun-27-25 08:33AM
5 Revealing Analyst Questions From Royalty Pharma's Q1 Earnings Call
(StockStory)
Jun-24-25 07:05AM
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion
(GlobeNewswire)
Jun-18-25 11:39PM
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
(StockStory)
Jun-12-25 07:26PM
Analyst Report: Royalty Pharma plc
(Morningstar Research)
Jun-09-25 09:54AM
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives
(StockStory)
Jun-04-25 04:15PM
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
(GlobeNewswire)
May-16-25 04:30PM
Royalty Pharma Completes the Acquisition of Its External Manager
(GlobeNewswire)
May-13-25 08:15AM
Royalty Pharma to Present at Upcoming Investor Conferences
(GlobeNewswire)
May-12-25 04:15PM
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
(GlobeNewswire)
May-08-25 08:03PM
Analyst Report: Royalty Pharma plc
(Morningstar Research)
10:30AM
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
(Zacks)
08:25AM
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
(Zacks)
07:15AM
Royalty Pharma Reports First Quarter 2025 Results
(GlobeNewswire)
May-07-25 12:34PM
Royalty Pharma Q1 2025 Earnings Preview
(Seeking Alpha)
May-05-25 09:15AM
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics
(Zacks)
May-01-25 10:01AM
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
(Zacks)
Apr-28-25 06:50PM
Alerus (ALRS) Q1 Earnings and Revenues Top Estimates
(Zacks)
Apr-24-25 08:16AM
Royalty Pharma PLC (RPRX) Surged Following an Acquisition Announcement
(Insider Monkey)
07:36AM
Thomas: Fragile is the word we agreed on
(CNBC TV)
Apr-22-25 12:00PM
Patient Capital Management Q1 2025 Investment Review
(Seeking Alpha)
11:20AM
Patient Capital Management Q1 2025 Commentary
(Seeking Alpha)
Apr-21-25 04:15PM
Royalty Pharma Declares Second Quarter 2025 Dividend
(GlobeNewswire)
Apr-17-25 04:15PM
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
(GlobeNewswire)
Apr-10-25 06:20AM
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
(Zacks)
Apr-08-25 04:15PM
Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors
(GlobeNewswire)
Apr-02-25 09:47AM
Is Royalty Pharma plc (RPRX) The Most Profitable Biotech Stock To Buy Right Now?
(Insider Monkey)
Apr-01-25 10:00AM
Is Royalty Pharma Plc (RPRX) the Most Undervalued Healthcare Stock to Buy According to Analysts?
(Insider Monkey)
06:20AM
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
(Zacks)
Mar-29-25 07:15AM
4 Healthcare Stocks With Massive Gains-and More to Come
(MarketBeat)
Mar-27-25 08:15AM
Royalty Pharma Announces Upcoming Investor Day
(GlobeNewswire)
Mar-26-25 11:43AM
3 Reasons to Sell RPRX and 1 Stock to Buy Instead
(StockStory) -6.52%
Mar-25-25 09:19PM
Is Royalty Pharma plc (RPRX) The Best Defensive Stock Amid Market Volatility?
(Insider Monkey)
Mar-21-25 11:30AM
Why Is Blue Owl Capital Corporation (OBDC) Down 3% Since Last Earnings Report?
(Zacks)
05:12AM
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
(StockStory)
Feb-27-25 04:15PM
Royalty Pharma to Present at TD Cowen's 45th Annual Health Care Conference
(GlobeNewswire)
Feb-23-25 03:03PM
Why Royalty Pharma Plc (RPRX) is the Best Performing Pharma Stock So Far in 2025
(Insider Monkey)
Feb-13-25 07:57PM
Analyst Report: Royalty Pharma plc
(Morningstar Research)
Feb-12-25 09:06AM
Analyst Report: Royalty Pharma plc
(Morningstar Research)
06:30AM
Royalty Pharma Announces R&D Funding Collaboration With Biogen
(GlobeNewswire)
02:07AM
Royalty Pharma PLC (RPRX) Q4 2024 Earnings Call Highlights: Strong Financial Performance and ...
(GuruFocus.com)
Feb-11-25 07:33AM
Royalty Pharma (NASDAQ:RPRX) Misses Q4 Revenue Estimates
(StockStory)
07:15AM
Royalty Pharma Reports Q4 and Full Year 2024 Results
(GlobeNewswire)
Feb-10-25 08:03AM
Royalty Pharma Earnings: What To Look For From RPRX
(StockStory)
Jan-29-25 09:00AM
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
(GlobeNewswire)
Jan-28-25 04:15PM
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
(GlobeNewswire)
Jan-23-25 06:29AM
Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now?
(Insider Monkey)
Jan-15-25 01:52PM
Royalty Pharma plc (RPRX): Analysts Recommend This 52-Week High Stocks Now
(Insider Monkey)
Jan-12-25 11:24AM
Heres Why Royalty Pharma plc (RPRX) Led This Weeks Rally
(Insider Monkey)
Jan-11-25 01:10PM
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?
(Insider Monkey)
Jan-10-25 07:30AM
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) +12.56%
07:15AM
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
(GlobeNewswire)
Jan-09-25 04:15PM
Royalty Pharma Announces Dividend Increase
(GlobeNewswire)
Dec-27-24 05:47AM
Jim Cramer on Royalty Pharma plc (RPRX): Disappointing Stock, Man, I Cant Believe It
(Insider Monkey)
Dec-24-24 04:45AM
Jim Cramer Calls Royalty Pharma (RPRX) Disappointing But Recommends Holding I Want You To Stick With It
(Insider Monkey)
Dec-19-24 08:06PM
Lightning Round: MandT Bank is a buy, I like the banks, says Jim Cramer
(CNBC TV)
Nov-27-24 04:15PM
Royalty Pharma to Present at Upcoming Investor Conferences
(GlobeNewswire)
11:11AM
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood?
(Insider Monkey)
Nov-14-24 04:30PM
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
(GlobeNewswire)
Nov-07-24 07:10AM
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million
(GlobeNewswire)
02:10AM
Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions
(GuruFocus.com)
12:08AM
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
(GuruFocus.com)
Nov-06-24 07:16PM
Analyst Report: Royalty Pharma plc
(Morningstar Research)
07:15AM
Royalty Pharma Reports Third Quarter 2024 Results
(GlobeNewswire)
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Norden GregoryDirectorAug 11 '25Sale36.2333,5001,213,749194,848Aug 11 04:35 PM
Norden GregoryDirectorAug 11 '25Proposed Sale36.2333,5001,213,747Aug 11 04:18 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.